Abstract
Objective: To investigate whether serum leucine-rich α2-glycoprotein (LRG) levels are elevated in patients with adult-onset Stills disease (AOSD) and determine their correlation with disease activity parameters.Method: We enrolled 39 patients with AOSD, 47 patients with rheumatoid arthritis (RA), and 39 controls. Forty-five serum samples from the patients with AOSD were assayed for LRG using an enzyme-linked immunosorbent assay (ELISA). Comprehensive AOSD activity was determined by a modified Pouchot score.Results: Serum LRG levels were significantly elevated in patients with AOSD (128.8 ± 40.8 ng/mL) compared to those in patients with RA and in controls (33.9 ± 15.2 ng/mL, p < 0.001 and 22.4 ± 6.1 ng/mL, p < 0.001, respectively). Patients with active AOSD had significantly higher LRG levels than those with inactive disease (141.4 ± 31.3 ng/mL vs. 79.8 ± 37.1 ng/mL, p = 0.002). Serum LRG levels were positively correlated with C-reactive protein (CRP; γ = 0.387, p = 0.015), lactate dehydrogenase (LDH; γ = 0.370, p = 0.026), ferritin (γ = 0.687, p < 0.001) levels, and the modified Pouchot score (γ = 0.756, p < 0.001). Serum LRG levels decreased significantly after treatment in all six patients with active AOSD who had follow-up evaluations (p = 0.007). The best cut-off value for LRG to distinguish AOSD from RA was 67.9 ng/mL, with a sensitivity of 92.3% and a specificity of 97.9%.Conclusions: Serum LRG levels were increased in patients with AOSD and correlated well with disease activity measures. LRG may be a useful biomarker for distinguishing AOSD from RA and for monitoring the disease activity of AOSD.
| Original language | English |
|---|---|
| Pages (from-to) | 399-403 |
| Number of pages | 5 |
| Journal | Scandinavian Journal of Rheumatology |
| Volume | 44 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2015 Sep 3 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Rheumatology
- Immunology
Cite this
}
Serum leucine-rich α2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Stills disease. / Ha, Y. J.; Kang, E. J.; Lee, S. W.; Park, Y. B.; Lee, S. K.; Song, J. S.; Choi, S. T.
In: Scandinavian Journal of Rheumatology, Vol. 44, No. 5, 03.09.2015, p. 399-403.Research output: Contribution to journal › Article
TY - JOUR
T1 - Serum leucine-rich α2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Stills disease
AU - Ha, Y. J.
AU - Kang, E. J.
AU - Lee, S. W.
AU - Park, Y. B.
AU - Lee, S. K.
AU - Song, J. S.
AU - Choi, S. T.
PY - 2015/9/3
Y1 - 2015/9/3
N2 - Objective: To investigate whether serum leucine-rich α2-glycoprotein (LRG) levels are elevated in patients with adult-onset Stills disease (AOSD) and determine their correlation with disease activity parameters.Method: We enrolled 39 patients with AOSD, 47 patients with rheumatoid arthritis (RA), and 39 controls. Forty-five serum samples from the patients with AOSD were assayed for LRG using an enzyme-linked immunosorbent assay (ELISA). Comprehensive AOSD activity was determined by a modified Pouchot score.Results: Serum LRG levels were significantly elevated in patients with AOSD (128.8 ± 40.8 ng/mL) compared to those in patients with RA and in controls (33.9 ± 15.2 ng/mL, p < 0.001 and 22.4 ± 6.1 ng/mL, p < 0.001, respectively). Patients with active AOSD had significantly higher LRG levels than those with inactive disease (141.4 ± 31.3 ng/mL vs. 79.8 ± 37.1 ng/mL, p = 0.002). Serum LRG levels were positively correlated with C-reactive protein (CRP; γ = 0.387, p = 0.015), lactate dehydrogenase (LDH; γ = 0.370, p = 0.026), ferritin (γ = 0.687, p < 0.001) levels, and the modified Pouchot score (γ = 0.756, p < 0.001). Serum LRG levels decreased significantly after treatment in all six patients with active AOSD who had follow-up evaluations (p = 0.007). The best cut-off value for LRG to distinguish AOSD from RA was 67.9 ng/mL, with a sensitivity of 92.3% and a specificity of 97.9%.Conclusions: Serum LRG levels were increased in patients with AOSD and correlated well with disease activity measures. LRG may be a useful biomarker for distinguishing AOSD from RA and for monitoring the disease activity of AOSD.
AB - Objective: To investigate whether serum leucine-rich α2-glycoprotein (LRG) levels are elevated in patients with adult-onset Stills disease (AOSD) and determine their correlation with disease activity parameters.Method: We enrolled 39 patients with AOSD, 47 patients with rheumatoid arthritis (RA), and 39 controls. Forty-five serum samples from the patients with AOSD were assayed for LRG using an enzyme-linked immunosorbent assay (ELISA). Comprehensive AOSD activity was determined by a modified Pouchot score.Results: Serum LRG levels were significantly elevated in patients with AOSD (128.8 ± 40.8 ng/mL) compared to those in patients with RA and in controls (33.9 ± 15.2 ng/mL, p < 0.001 and 22.4 ± 6.1 ng/mL, p < 0.001, respectively). Patients with active AOSD had significantly higher LRG levels than those with inactive disease (141.4 ± 31.3 ng/mL vs. 79.8 ± 37.1 ng/mL, p = 0.002). Serum LRG levels were positively correlated with C-reactive protein (CRP; γ = 0.387, p = 0.015), lactate dehydrogenase (LDH; γ = 0.370, p = 0.026), ferritin (γ = 0.687, p < 0.001) levels, and the modified Pouchot score (γ = 0.756, p < 0.001). Serum LRG levels decreased significantly after treatment in all six patients with active AOSD who had follow-up evaluations (p = 0.007). The best cut-off value for LRG to distinguish AOSD from RA was 67.9 ng/mL, with a sensitivity of 92.3% and a specificity of 97.9%.Conclusions: Serum LRG levels were increased in patients with AOSD and correlated well with disease activity measures. LRG may be a useful biomarker for distinguishing AOSD from RA and for monitoring the disease activity of AOSD.
UR - http://www.scopus.com/inward/record.url?scp=84943235112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943235112&partnerID=8YFLogxK
U2 - 10.3109/03009742.2015.1016103
DO - 10.3109/03009742.2015.1016103
M3 - Article
C2 - 26079682
AN - SCOPUS:84943235112
VL - 44
SP - 399
EP - 403
JO - Scandinavian Journal of Rheumatology
JF - Scandinavian Journal of Rheumatology
SN - 0300-9742
IS - 5
ER -